Mike:
A diversified portfolio of second- and third-tier biotechs, up 100% in 45 weeks (tax cost as shown includes sales profits, all portfolios for the T/FIF thread originated with 100K). Outperformed BTK, despite the huge summer and fall for top-tier. Far outperformed Franklin (weighting, timing and conceptual issues), the only pure play in a biotech mutual fund.........
exchange2000.com
exchange2000.com
The portfolio was put together in the "spirit" of some of biotech's best at SI for '98, Jim Silverman, Vector 1, and Peter Suzman. Many, many at SI participated in refinements. Simply investing in Biogen would have outperformed the portfolio, but, it's made a point..... there's value in good science, even while the sector is taking a publicity beating.
Good indications/foci, going forward..... genomics started hopping last week, investors are beginning to look at depressed "research premiums", and the third-tier is still deeply discounted.
Cheers! Rick |
